Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.
Launched by PEKING UNIVERSITY THIRD HOSPITAL · May 17, 2024
Trial Information
Current as of February 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • (1) Stage IB3 to IVA disease based on the 2018 International Federation of Gynecology and Obstetrics (FIGO) system;
- • (2) Eastern Cooperative Oncology Group at 2 or less;
- • (3) Life expectancy of greater than 3 months;
- • (4) Left ventricular ejection fraction at ≥55%;
- • (5) Neutrophil count at ≥1500/mm\^3, platelet count at ≥100,000/mm\^3 or hemoglobin at ≥9.0 g/dL;
- • (6) Serum creatinine at \<1.5 times the upper limit of the normal reference range;
- • (7) Alanine transaminase or aspartate aminotransferase at \>2.5 times the upper limit of the normal reference range;
- • (8) Non pregnant or lactating women;
- • (9) Women of childbearing age willing to adopt reliable contraceptive measures;
- • (10) Sign informed consent form.
- Exclusion Criteria:
- • (1) Individuals who have previously received chemotherapy with albumin bound paclitaxel;
- • (2) Individuals who have previously received abdominal or pelvic radiation therapy;
- • (3) Individuals who have received neoadjuvant chemotherapy or targeted, immunotherapy, and other anti-tumor treatments prior to concurrent chemoradiotherapy and chemotherapy;
- • (4) Individuals with central nervous system diseases or brain metastases;
- • (5) Other malignant tumors other than cervical cancer have appeared within the past 5 years;
- • (6) Previously experienced sensory or motor neuropathy (Grade ≥ 2) ;
- • (7) The researchers evaluate that the uncontrolled serious medical diseases that will affect the ability of the participants to receive the treatment of the clinical trial, such as complicated with serious medical diseases, including serious heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc;
- • (8) known to be allergic to paclitaxel;
- • (9) Received other experimental drugs or participated in clinical studies for other anti-cancer treatment purposes within 30 days of the first chemotherapy administration;
- • (10) Serious infections occurring within 4 weeks prior to the start of research treatment, including but not limited to complications of infection requiring hospitalization, bacteremia, or severe pneumonia;
- • (11) Human immunodeficiency virus (HIV) positive individuals;
- • (12) Uncontrolled or active viral hepatitis or infection with human immunodeficiency virus;
- • (13) Researchers determine that it is not suitable to participate in this study.
Trial Officials
Ping Jiang, Doctor
Principal Investigator
Peking University Third Hospital
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0